Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25418201 | 0.80 | LPL (0.46) | LPLLIPGP2RX7 | |
| SCHEMBL327717 | 0.79 | LPL (0.40) | LPLLIPGP2RX7 | |
| SCHEMBL15315303 | 0.77 | LPL (0.38) | LPLLIPG | |
| SCHEMBL10269418 | 0.77 | LPL (0.39) | LPLLIPGP2RX7 | |
| SCHEMBL13429482 | 0.77 | LPL (0.39) | LPLLIPGP2RX7 | |
| SCHEMBL29276139 | 0.77 | LPL (0.39) | LPLLIPGP2RX7 | |
| SCHEMBL443424 | 0.77 | LPL (0.39) | LPLLIPGP2RX7 | |
| SCHEMBL30557650 | 0.75 | LPL (0.46) | LPLLIPG | |
| SCHEMBL25366073 | 0.75 | LPL (0.46) | LPLLIPG | |
| SCHEMBL2524790 | 0.74 | TAAR1 (0.39) | LPLLIPGP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4186897-A1 | PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3670506-B1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-108715590-B | Thiazolecarboxamide and picolinamide compounds useful as PIM kinase inhibitors | 因赛特公司 | 2022-03-08 | — | — | CN | disclosed |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2020-12-31 | — | — | US | disclosed |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2020-12-31 | — | — | US | disclosed |
| US-10828290-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-10828290-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3670506-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | Incyte Holdings Corporation (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2012120415-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012120415-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | PIM1, PIM2, PIM3 | LPL 3705/4885LIPG 1883/4885P2RX7 3214/4885 |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | LPL 3411/4885LIPG 3035/4885P2RX7 2818/4885 |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | PIM2, PIM1, PIM3 | LPL 3411/4885LIPG 3035/4885P2RX7 2818/4885 |
| US-10828290-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | PIM2, PIM1, PIM3 | LPL 3411/4885LIPG 3035/4885P2RX7 2818/4885 |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | LPL 4541/4885LIPG 3349/4885P2RX7 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.